---
title: "Shandong Sito Bio-technology Co., Ltd. (300583.SZ)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/300583.SZ.md"
symbol: "300583.SZ"
name: "Shandong Sito Bio-technology Co., Ltd."
industry: "Pharmaceuticals"
datetime: "2026-05-20T14:41:41.238Z"
locales:
  - [en](https://longbridge.com/en/quote/300583.SZ.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/300583.SZ.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/300583.SZ.md)
---

# Shandong Sito Bio-technology Co., Ltd. (300583.SZ)

## Company Overview

Shandong Sito Bio-technology Co., Ltd. researches, develops, and produces steroid biomedicine intermediates. Its products include 9a-hydroxyandrost, 17a-hydroxyprogesterone, 17a-hydroxy progesterone derivatives, anecort acetate, neomycin sulfate, progesterone intermediate, tylvalosin tartrate, tetraene acetate, androstenedione, bisnoralcohol, norandrostenedione, ethylene deltenone, 16ß and 16a methyl epoxide, and hexahydro-3a-methyl, as well as androsta-1,4-diene-3,17-dione and estra-4,9-diene-3,17-dione. Shandong Sito Bio-technology Co., Ltd.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | CN Market |
| Website | [www.sitobiotech.com](https://www.sitobiotech.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: D
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:09.000Z

**Overall: D (0.69)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 0 / 215 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: D

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 0.00% |  |
| Net Profit YoY | 0.00% |  |
| P/B Ratio | 1.60 |  |
| Dividend Ratio | 0.13% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 2827788507.24 |  |
| Revenue | 956453848.08 |  |

#### Multi Score Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -9.31% | D |
| Profit Margin | -18.09% | D |
| Gross Margin | 23.44% | C |
| Revenue YoY | -14.87% | E |
| Net Profit YoY | -20505.88% | E |
| Total Assets YoY | -7.16% | E |
| Net Assets YoY | -9.88% | D |
| Cash Flow Margin | -59.79% | E |
| OCF YoY | -14.87% | E |
| Turnover | 0.32 | D |
| Gearing Ratio | 37.15% | B |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Shandong Sito Bio-technology Co., Ltd.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "0.00%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "0.00%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "1.60",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.13%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "2827788507.24",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "956453848.08",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "-9.31%",
          "rating": "D"
        },
        {
          "name": "Profit Margin",
          "value": "-18.09%",
          "rating": "D"
        },
        {
          "name": "Gross Margin",
          "value": "23.44%",
          "rating": "C"
        },
        {
          "name": "Revenue YoY",
          "value": "-14.87%",
          "rating": "E"
        },
        {
          "name": "Net Profit YoY",
          "value": "-20505.88%",
          "rating": "E"
        },
        {
          "name": "Total Assets YoY",
          "value": "-7.16%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "-9.88%",
          "rating": "D"
        },
        {
          "name": "Cash Flow Margin",
          "value": "-59.79%",
          "rating": "E"
        },
        {
          "name": "OCF YoY",
          "value": "-14.87%",
          "rating": "E"
        },
        {
          "name": "Turnover",
          "value": "0.32",
          "rating": "D"
        },
        {
          "name": "Gearing Ratio",
          "value": "37.15%",
          "rating": "B"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -66.13 | 205/215 | - | - | - |
| PB | 1.57 | 49/215 | 1.82 | 1.61 | 1.55 |
| PS (TTM) | 2.56 | 60/215 | 3.38 | 3.03 | 2.79 |
| Dividend Yield | 0.14% | 153/215 | 0.15% | 0.14% | 0.13% |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Allist (688578.SH) | A | A | B | A | B | A |
| 02 | Xingqi Pharmaceutical (300573.SZ) | A | A | A | A | B | A |
| 03 | Hengrui Pharma (600276.SH) | A | B | C | A | B | B |
| 04 | Yunnan Baiyao (000538.SZ) | B | C | B | B | C | B |
| 05 | Haisco (002653.SZ) | A | A | B | B | B | B |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/300583.SZ/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/300583.SZ/norm.md)
- [Related News](https://longbridge.com/en/quote/300583.SZ/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/300583.SZ/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**